Suraxavir marboxil (GP681) is an orally available prodrug that is converted in vivo to the active metabolite GP1707D07, a PA-targeting antiviral against influenza. Because GP1707D07 is primarily ...

Scientists explored selectively blocking the CYP3A4 protein responsible for breaking down large swaths of approved drugs, providing a way to improve drug efficacy. Scientists at St. Jude Children's ...

(MEMPHIS, Tenn. – April 10, 2025) Cytochrome P450 (CYP) proteins are responsible for breaking down more than 80% of all Food and Drug Administration (FDA) approved drugs, reducing their effectiveness.

(RTTNews) - Biopharmaceutical company Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced Thursday positive data from its recently completed clinical drug-drug interaction (DDI) study investigating ...